Italy Cancer Immunotherapy Market Size & Outlook
Italy cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
Italy cancer immunotherapy market highlights
- The Italy cancer immunotherapy market generated a revenue of USD 3,791.7 million in 2023 and is expected to reach USD 6,816.3 million by 2030.
- The Italy market is expected to grow at a CAGR of 8.7% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer immunotherapy market data book summary
| Market revenue in 2023 | USD 3,791.7 million |
| Market revenue in 2030 | USD 6,816.3 million |
| Growth rate | 8.7% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, Italy accounted for 3.0% of the global cancer immunotherapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2030.
- Spain is the fastest growing regional market in Europe and is projected to reach USD 6,410.1 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 65.71% in 2023. Horizon Databook has segmented the Italy cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
The Italy cancer immunotherapy market is mainly driven by rising disease incidence, latest epidemiological data findings, proactive government initiatives, and increasing funds for cancer research & new product development. The proactive participation of oncology companies in this market is a major factor boosting the market.
For instance, the Phylogeny, a Swiss-Italian biotechnology company, raised USD 67.15 million to accelerate two major cancer programs soft tissue sarcoma and late-stage melanoma. The immunotherapeutic approach is based on cytokines and has been nicknamed “guided missile” therapy.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Italy cancer immunotherapy market size, by product, 2018-2030 (US$M)
Italy Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
